June 30 (Reuters) – Amplia Therapeutics Ltd:
RECEIVED PRELIMINARY FINAL RESULTS FROM PRECLINICAL TOXICOLOGY STUDIES BEING CONDUCTED WITH ITS FAK INHIBITOR, AMP945
PRECLINICAL TOXICOLOGY STUDIES SUPPORT PLANNED PHASE 1 CLINICAL TRIAL Present textual inform for Eikon: Additional firm protection:
Our Requirements: The Thomson Reuters Believe Rules.
